Relative Bioavailability of a Fixed-Combination Tablet Formulation of Azithromycin and Chloroquine in Healthy Adult Subjects

Qinying Zhao*, Vivek Purohit, Jenny Cai, Robert R. LaBadie and Richa Chandra

Pfizer Inc, Groton, Connecticut, USA

Abstract

A fixed-dose combination of azithromycin and chloroquine (AZCQ) is in development for intermittent preventive treatment of malaria in pregnant women (IPTp). The combination has demonstrated synergistic activity against chloroquine-resistant strains of Plasmodium falciparum in vitro and in vivo and efficacy in Phase 2 and 3 treatment studies in patients with symptomatic uncomplicated P. falciparum malaria. This was an open-label, randomized, single-dose, parallel-group study to estimate the relative bioavailability of two AZCQ tablets, each containing azithromycin base 250 mg and chloroquine base 155 mg (test treatment), compared with the coadministration of commercially available individual tablets of azithromycin base 500 mg and chloroquine base 300 mg (reference treatment) in 40 healthy male and female subjects (aged 18-55 years; body weight >50.0 kg). Fasting subjects were randomized 1:1 to receive either test or reference treatment. Blood samples for the determination of serum azithromycin and plasma chloroquine concentrations were collected at specified time points pre- and post-dose for noncompartmental pharmacokinetic analyses. Safety evaluations included monitoring adverse events and vital signs as well as performing clinical laboratory tests. All subjects completed the study. Area under the concentration–time curve from time zero to time of last measurable concentration (AUClast) of azithromycin and chloroquine for the two AZCQ tablets was comparable to the reference treatment. The relative bioavailability as measured by AUCtest/AUCref ratio of adjusted geometric means (90% confidence interval) for the two AZCQ tablets was 101% (85.4%, 119%) for azithromycin and 99.1% (84.0%, 117%) for chloroquine compared with the reference treatment. Maximum concentration values for the two AZCQ tablets were approximately 13.0% higher for azithromycin and 11.0% lower for chloroquine compared with reference treatment. Both treatments were well tolerated. This AZCQ tablet formulation is currently being evaluated in Phase 3 clinical trials for IPTp.

Keywords: Azithromycin; Chloroquine; Bioavailability; Pharmacokinetics

Abbreviations: AE: Adverse Event; AUClast: Area Under The Concentration–Time Curve from Time Zero to Time of Last Measurable Concentration; AZ: Azithromycin; AZCQ: Fixed-Dose Combination Tablet of Azithromycin and Chloroquine; CI: Confidence Interval; Cmax: Maximum Concentration; CQ: Chloroquine; CV: Coefficient of Variation; HPLC-MS/MS: High-Performance Liquid Chromatography Tandem Mass Spectrometry; IPTp: Intermittent Preventive Treatment of Malaria in Pregnant Women; K3EDTA: Tri-Potassium Ethylene Diamine Tetra-Acetic Acid; PK: Pharmacokinetics; SP: Sulfadoxine Pyrimethamine; Tmax: Time To Maximum Concentration

Introduction

Malaria in pregnancy is one of the most common preventable causes of maternal and neonatal mortality and morbidity in developing countries; approximately 125 million pregnancies are at risk every year [1]. Sulfadoxine-pyrimethamine (SP) is the current standard of care for intermittent preventive treatment of pregnant women (IPTp) in areas with high and stable malaria transmission [2]. AZCQ, a fixed-dose combination tablet of azithromycin (AZ) and chloroquine (CQ), is being developed for IPTp as a potential alternative to SP.

There is a strong rationale for developing AZCQ for IPTp. First, the combination of AZ and CQ has demonstrated synergistic activity against CQ-resistant strains of Plasmodium falciparum in vitro and in vivo [3-5]. Coadministration of AZ and CQ has demonstrated over 95% efficacy in Phase 2 and 3 clinical trials in Africa, Latin America, and India, irrespective of the rates of CQ resistance [4,6,7]. Furthermore, AZ and CQ have been on the market for many years individually and have extensive safety data in adults, children, and pregnant women [8]. The safety of the combination/coadministration of AZ and CQ has been documented in more than 1,000 subjects [8]. Additionally, there is no evidence of a clinically relevant pharmacokinetic (PK) interaction between AZ and CQ in healthy subjects [9]. Finally, the growing resistance to SP has become a cause of serious concern, especially in East and South Africa, and there is an urgent need to develop alternatives to SP [10].

AZCQ, a combination of AZ base 250 mg and CQ base 155 mg, has been developed specifically for use in IPTp and is likely to provide a convenient dosage form with improved compliance. The aim of this study was to evaluate the relative bioavailability of AZCQ tablets compared with coadministered commercially available individual tablets of AZ and CQ in healthy adult subjects (ClinicalTrials.gov identifier NCT00844207).

Methods

Study design and subjects

This study was an open-label, randomized, single-dose, parallel-
group clinical pharmacology study. Healthy male and female subjects aged 18 to 55 years with body mass index 17.5 to 30.5 kg/m² and total body weight greater than 50.0 kg were included in the study. Individuals with evidence of illness before study treatment (fever within 5 days before the first dose, acute or chronic infectious disease within 15 days before the first dose of study treatment) were excluded from participation. Additional exclusion criteria included any condition possibly affecting drug absorption; treatment with an investigational drug within 30 days or five half-lives before the first dose of study treatment; use of prescription or nonprescription drugs and/or dietary supplements within 7 days or five half-lives before the first dose of study treatment; excessive use of tobacco- or nicotine-containing products (equivalent of more than five cigarettes per day) or a history of regular alcohol consumption within 6 months of screening; electrocardiogram demonstrating corrected QT interval greater than 450 msec at screening; history of significant cardiovascular disease; or history of intolerance to AZ or CQ. Females who were pregnant or nursing were also excluded.

Subjects were randomized in a 1:1 ratio to one of the following single-dosage treatments given at approximately 8:00 AM (± 2 hours) after an overnight fast of 8 hours. Treatment A (test treatment) included two AZCQ tablets (AZ base 250 mg/CQ base 155 mg for each tablet)2*. Treatment B (reference treatment) included a single commercially available tablet of AZ (Zithromax®, Pfizer Inc., New York, NY) containing a 500-mg dose base and a single tablet of CQ (Aralen®, Sanofi Aventis, Bridgewater, NJ) containing a 300-mg dose base. Subjects were confined to the clinical research unit for at least 2 days, with follow-up visits on Days 3, 4, and 5 for PK blood sample collections.

Systemic exposure parameters (maximum drug concentration [Cmax], area under the drug concentration–time profile from zero time to the time of the last quantifiable concentration [AUClast]) for AZ and CQ were calculated and compared between the two treatment groups. Time to Cmax (Tmax) was also estimated. Because of the long half-life of both AZ and CQ, a crossover study design would have been logistically challenging due to long trial duration and potential subject withdrawals. Therefore, the two treatments were administered in a parallel manner, and blood samples were collected at specified time points from both groups for 96 hours post dose.

This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonisation Good Clinical Practice guidelines. The study protocol and consent documentation were reviewed and approved by the Institutional Review Board at the participating study center, a fully accredited board located in Austin, Texas. All subjects provided informed consent before entering the study.

Pharmacokinetic evaluations

Blood samples (3 mL) for determination of AZ concentrations in serum were collected into appropriately labeled tubes containing no preservative or anticoagulant or serum separator at pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post dose. The whole blood samples remained at room temperature until clotted (approximately 30 minutes). Samples were then centrifuged at 1,700 X g for approximately 10 minutes at 4°C. The serum was transferred into appropriately labeled screw-capped polypropylene tubes and stored at -20°C within 1 hour of collection. Serum samples were analyzed for AZ concentrations using a validated high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) assay.

In addition, blood samples (4 mL) for determination of CQ concentrations in plasma were also collected into appropriately labeled tubes containing tri-potassium ethylene diamine tetra-acetic acid (K3EDTA) at pre-dose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post dose. Samples were centrifuged at 1,700 X g for approximately 10 minutes at 4°C. The plasma was transferred into appropriately labeled screw-capped polypropylene tubes and stored at -20°C within 1 hour of collection. Samples were analyzed for determination of CQ concentrations using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) assay. The evaluated PK parameters are detailed in table 1.

Analytical methods

Bioanalytical Systems Ltd (Warwickshire, UK) analyzed serum samples for AZ concentrations using a HPLC-MS/MS method, following a liquid-liquid extraction. For the serum sample, 100 µL of D3-azithromycin (internal standard, 50.0 ng/mL) in acetonitrile-water (1:1 vol/vol) was added to 50 µL of serum, followed by the addition of 50 µL of 50 mM ammonium and 500 µL of methyl tertiary butyl ether in a TomTec 96-well format. After brief vortexing (2 minutes), the samples were centrifuged at 4,000 rpm for 5 minutes to separate the layers. The upper ether layer was transferred to a 96-well plate and evaporated under nitrogen at 40°C. The dried extract was reconstituted with 200 µL of the mobile phase (35% acetonitrile – 65% 50 mM ammonium, vol/vol). After brief vortexing (1 minute), the samples were centrifuged at 2,500 rpm for 5 minutes. A 50 µL aliquot was injected into an LC-MS/MS system (BS AM-80 pump with an LC-26B on-line vacuum degasser and a PE Sciex API-3000 LC-MS/MS system) set up with a Zorbax Eclipse XDB-C8 column (2.1×150 mm, 5 µm). The mass spectrometer was operated in the positive ionization mode and monitored the transition ions m/z 749.5→591.4 and 752.6→594.1 for AZ and D3-azithromycin, respectively. The dynamic range for the serum assay was 10.0 to 500 ng/mL. The conditions for stability for freeze/thaw, matrix, processed extract, and long-term in frozen matrix were 3-cycles at -20ºC/ambient temperature, 25 hours at ambient

| Parameter | Definition | Method of Determination |
|-----------|------------|------------------------|
| Cmax      | Maximum drug concentration | Observed directly from data |
| Tmax      | Time to Cmax | Observed directly from data as time of first occurrence |
| AUClast   | Area under the drug concentration–time profile from time zero to the time of last quantifiable concentration | Linear/log trapezoidal method |

Table 1: Pharmacokinetic parameters determined for azithromycin and chloroquine.
temperature, 54 hours at ambient temperature, and 413 days at -20°C ± 50°C, respectively. The mean percent recovery for AZ was 100%. The accuracy of the quality control samples used during the sample analysis ranged from -2.1% to 4.7%, with a precision of 2.5% to 4.7%. In 11 analytical runs for all serum samples, all runs were acceptable.

Cetero Research (Houston, TX, USA) analyzed plasma samples for CQ concentrations using a LC-MS/MS method. CQ was determined following a liquid-liquid extraction. Each 200 µL plasma sample was mixed with 1 mL of protriptyline hydrochloride (internal standard solution, 20.0 ng/mL) and 50 µL of 4.5 M ammonium hydroxide solution. After vortexing, 5 mL of methyl tertiary butyl ether was added and the sample was shaken for 5 minutes and centrifuged for 5 minutes at 3,000 rpm. The organic layer was transferred to a culture tube and 20 µL of 0.1% formic acid in methanol solution w 1:1. vol/vol) was added as added. The organic layer was evaporated to dryness at 400°C under a gentle stream of air. The dried extract was reconstituted with 1 mL of the mobile phase (mixture of 700 mL of methanol with 300 mL of deionized water and 2.5 mL of 1.0 M ammonium trifluoroacetate solution) and 5 µL was injected onto a LC-MS/MS system (PE Series 200 LC pump with API-3000/4000 LC-MS/MS system (equipped with Turbo Ion Spray) set up with a Beta Basic CN (Keystone) column (2.1x100 mm, 5 µm) equipped with In-line pre-column filter. The mass spectrometer was operated in the positive ionization MRM mode and monitored the transition ions m/z 320.2→247.0 and 264.1→155.1 for CQ and protriptyline, respectively. The dynamic range for the serum assay was 1.00 to 500 ng/mL. The conditions for stability for freeze/thaw, matrix, processed extract, and long-term in frozen matrix were 6-cycles at -20°C ± 10°C/ambient temperature, 24 hours at ambient temperature, 48 hours at ambient temperature, and 1886 days at -20°C ± 10°C, respectively. The mean percent recovery for CQ was 80.8%. The accuracy of the quality control samples used during sample analysis ranged from -0.4% to 3.0%, with a precision of 8.9%. In 11 analytical runs for all serum samples, all runs were acceptable.

Safety evaluations

Adverse events (AEs), clinical laboratory tests, and vital signs were monitored throughout the study. A complete physical examination, including 12-lead electrocardiogram, was done at screening and a limited physical examination was done on Day 5.

Statistical methods

The sample size of 40 subjects was empirically determined. However, 20 subjects per cohort would have provided a 90% confidence interval (CI) for the difference between treatments of ±0.185 and ±0.218 for AZ and ±0.163 and ±0.160 for CQ on the natural log scale for AUClast and Cmax, respectively, with 80% coverage probability.

Three analysis sets were defined for this study: 1) PK concentration population, which included all randomized and treated subjects with at least one concentration; 2) PK parameter analysis population, which included all randomized and treated subjects with at least one PK parameter of primary interest; and 3) safety analysis set, which included all subjects who received at least one dose of study medication.

A one-way analysis of variance model was used to analyze natural log-transformed AUClast and Cmax of both AZ and CQ separately by analyte. Estimates of the adjusted mean differences (test-reference) and corresponding 90% CI were obtained from the model. The adjusted mean differences and 90% CI for the differences were exponentiated to provide estimates of the ratios of adjusted geometric means (test/reference) and 90% CI for the ratios. Relative bioavailability was estimated as the ratio of adjusted geometric means for test treatment and reference treatment for AUClast. PK parameters (AUClast, Cmax, and Tmax) were summarized descriptively by analyte and treatment.

Results

Subject disposition and demographics

A total of 40 subjects were randomized and all completed the study (Table 2). Most (34/40; 85%) subjects were male; the proportion of male and female subjects was broadly similar in the two groups. Mean age was approximately 35 years in both groups. Sixty percent (24/40) of subjects were black; the distribution of race was similar in both groups. Mean weight, height, and body mass index were similar in the two groups.

Pharmacokinetics

Serum azithromycin pharmacokinetics: Mean and median serum AZ concentrations versus time profiles for the two treatment groups are presented as semi-log plots in figure 1a. The mean serum AZ concentration-time profiles with associated standard deviation (SD) are also presented as linear plots in figure 1b. The median drug concentrations between 30 minutes and 1 hour post dose were greater with the AZCQ tablet than with the coadministered commercially available individual tablets of AZ and CQ. After 3 hours post dose, the median serum AZ concentration–time profiles were approximately superimposable between the two treatment groups. The PK parameter values are descriptively summarized in table 3, and statistical analysis results of serum AZ exposure parameter for bioavailability assessment are presented in table 4. Variability in AUClast (coefficient of variation [CV] 30%–32%) and Cmax (CV, 38%–40%) estimates for AZ were similar between the two treatment groups (Table 3). The AUClast of AZ for the two AZCQ tablets was comparable to the reference treatment. The relative bioavailability of AZ, ie, ratio of adjusted geometric means (90% CI) of AUClast for the two AZCQ tablets was 101% (85.4%, 119%) compared with the reference treatment.

Maximum serum AZ concentrations were generally achieved by 0.5 to 3.0 hours post dose with both treatments (Table 3). The Cmax values of AZ for the two fixed-dose AZCQ tablets were approximately 13.0% higher than achieved with the reference treatment (Table 4).

| Characteristic | Combination Tablets (2xAzithromycin 250 mg/Chloroquine 155 mg) n=20 | Individual Tablets (Azithromycin 500 mg*Chloroquine 300 mg) n=20 |
|---------------|-------------------------------------------------|-------------------------------------------------|
| Age, years    | Mean (SD) Range (min-max)                      | Mean (SD) Range (min-max)                      |
|               | 35.2 (10.9) 24.0-54.0                           | 34.8 (8.1) 21.0-48.0                           |
| Weight, kg    | Mean (SD) Range (min-max)                      | Mean (SD) Range (min-max)                      |
|               | 78.9 (14.1) 56.0-103                            | 77.7 (9.4) 60.0-93.0                           |
| Height, cm    | Mean (SD) Range (min-max)                      | Mean (SD) Range (min-max)                      |
|               | 174 (9) 154-186                                | 174 (7) 161-186                                |
| Body mass index (kg/m²) Mean (SD) Range (min-max) | 25.8 (3.2) 19.5-30.0                           | 25.7 (2.9) 20.4-29.6                           |
| SD, standard deviation |                                       | Table 2: Summary of subject demographic characteristics. |
Plasma chloroquine pharmacokinetics: Mean and median plasma CQ concentrations versus time profiles for the two treatment groups are presented as semi-log plots in figure 2a. The mean plasma CQ concentration–time profiles with associated standard deviation (SD) are also presented as linear plots in figure 2b. The median CQ concentrations between 2 and 12 hours post dose were lower with the two AZCQ tablets than with the coadministered commercially available individual tablets of AZ and CQ. After 12 hours post dose, the median plasma CQ concentration–time profiles were similar between the two treatment groups.

The PK parameter values are descriptively summarized in table 3, and statistical analysis results of plasma CQ exposure parameter for bioavailability assessment are presented in table 4. Variability in AUC_{last} (CV, 30%–35%) and C_{max} (CV, 34%–36%) estimates for CQ were similar between the two treatment groups. The AUC_{last} estimates of CQ following the two treatments were similar. The ratio of adjusted geometric means of AUC_{last} following the administration of the two AZCQ tablets was 99.1% (90% CI, 84.0%, 117%) compared with the coadministered commercially available individual tablet of CQ. Therefore, the relative bioavailability value of the test treatment versus the reference treatment was 99.1% for CQ. The C_{max} values of CQ were generally achieved by 1 hour post dose for the fixed-dose AZCQ combination tablets and by 2 hours post dose for the coadministered commercially available individual tablet of CQ. The C_{max} value of CQ for the AZCQ combination tablets was approximately 11.0% lower than that observed following the coadministration of the commercially available individual tablets of AZ and CQ.

### Table 3: Summary of serum azithromycin and plasma chloroquine pharmacokinetic parameter values.

| Parameter (units) | Test | Reference | Ratio (%) | 90% Confidence Interval |
|-------------------|------|-----------|-----------|------------------------|
| **Azithromycin**  |      |           |           |                        |
| C_{max} (ng/mL)   | 496  | 437       | 113       | 91.6(141)              |
| AUC_{last} (ng•h/mL) | 3910 | 3880      | 101       | 85.4(119)              |
| **Chloroquine**   |      |           |           |                        |
| C_{max} (ng/mL)   | 95.8 | 108       | 89.0      | 74.4(106)              |
| AUC_{last} (ng•h/mL) | 3250 | 3281      | 99.1      | 84.0(117)              |

Test=2×azithromycin 250 mg/chloroquine 155 mg fixed-combination tablet. Reference=commercially available azithromycin 500 mg tablet+chloroquine 300 mg tablet. C_{max}=maximum concentration. AUC_{last}=area under the drug concentration–time profile from time zero to the time of last quantifiable concentration. *Adjusted geometric mean values. 

### Table 4: Summary of statistical analysis of pharmacokinetic parameters AUC_{last} and C_{max}.

| Parameter (units) | Test | Reference | Ratio (%) | 90% Confidence Interval |
|-------------------|------|-----------|-----------|------------------------|
| **Azithromycin**  |      |           |           |                        |
| C_{max} (ng/mL)   | 496  | 437       | 113       | 91.6(141)              |
| AUC_{last} (ng•h/mL) | 3910 | 3880      | 101       | 85.4(119)              |
| **Chloroquine**   |      |           |           |                        |
| C_{max} (ng/mL)   | 95.8 | 108       | 89.0      | 74.4(106)              |
| AUC_{last} (ng•h/mL) | 3250 | 3281      | 99.1      | 84.0(117)              |

Test=2×azithromycin 250 mg/chloroquine 155 mg fixed-combination tablet. Reference=commercially available azithromycin 500 mg tablet+chloroquine 300 mg tablet. C_{max}=maximum concentration. AUC_{last}=area under the drug concentration–time profile from time zero to the time of last quantifiable concentration. *Adjusted geometric mean values.
Safety

Both test and reference treatments were well tolerated, with no serious AEs, deaths, or discontinuations due to AEs reported. The most frequently reported AEs were gastrointestinal tract–related, diarrhea and nausea, each of which were reported in two subjects in the AZCQ group and 1 subject in the group coadministered the commercially available individual tablets of AZ and CQ. All AEs were mild to moderate in severity. Most AEs resolved without intervention.

Discussion

Based on systemic exposure, the results of this clinical pharmacology study showed comparable bioavailability of the two AZCQ tablets and the coadministered commercially available individual tablets of AZ and CQ. The small difference in C_{max} between the two treatments is unlikely to have a significant clinical impact. Both the AZCQ combination tablets and the coadministered commercially available individual tablets of AZ and CQ were well tolerated. Further, the development of a regimen of a fixed-dose AZCQ combination tablet formulation will greatly increase compliance by providing convenient dosing and will also decrease the likelihood of the development of resistance of \( P. falciparum \) to individual drug components of the tablet. Currently, this fixed-dose AZCQ combination tablet formulation is being evaluated in two ongoing Phase 3 studies on IPTp (ClinicalTrials.gov Identifiers: NCT01103713 and NCT01103063).

Acknowledgments

This study was sponsored by Pfizer Inc. Medical writing support was provided by Aruna Seth, PhD, of UBC Scientific Solutions and was funded by Pfizer Inc.

References

1. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO (2010) Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS Med 7: e1000221.
2. World Health Organization (2007) Malaria in pregnancy. Guidelines for measuring key monitoring and evaluation indicators.
3. Biswas S (2001) In-vitro antimalarial activity of azithromycin against chloroquine sensitive and chloroquine resistant Plasmodium falciparum. J Postgrad Med 47: 240-243.
4. Dunne MW, Singh N, Shukla M, Valecha N, Bhattacharyya PC, et al. (2005) A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J Infect Dis 191: 1582-1588.
5. Oert C, Willimgmyre GD, Lee P, Knirsch C, Milhous W (2002) Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 46: 2518-2524.
6. Chandra R (2007) A phase 3, randomized, open-label, comparative trial of azithromycin plus chloroquine versus mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in Africa. Proceedings of the 56th Annual Meeting of American Society of Tropical Medicine and Hygiene.
7. Chandra R, Lewis D, Morant D, Dubashi N, Sarkar S, et al. (2008) A phase 2 open-label, non-comparative trial of azithromycin 2 g plus chloroquine 600 mg base daily for three days for the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 79: 11.
8. Chico RM, Chandramohan D (2011) Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy. Expert Opin Drug Metab Toxicol 7: 1153-1167.
9. Cook JA, Randiniteis EJ, Bramson CR, Wescle DL (2006) Lack of a pharmacokinetic interaction between azithromycin and chloroquine. Am J Trop Med Hyg 74: 407-412.
10. Greenwood B, Alonso P, ter Kuile FO, Hill J, Steketee RW (2007) Malaria in pregnancy: priorities for research. Lancet Infect Dis 7: 169-174.